My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Summit Therapeutics

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics
Via Business Wire
Tickers SMMT
HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025
From Summit Therapeutics
Via Business Wire
Tickers SMMT
Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC
From Summit Therapeutics
Via Business Wire
Tickers SMMT
Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025
From Summit Therapeutics
Via Business Wire
Tickers SMMT
Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025
From Summit Therapeutics
Via Business Wire
Tickers SMMT
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025
From Summit Therapeutics
Via Business Wire
Tickers SMMT
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.